Cutia Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cutia Therapeutics has been growing earnings at an average annual rate of 73%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 341.4% per year.
Key information
73.0%
Earnings growth rate
91.9%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 341.4% |
| Return on equity | -44.1% |
| Net Margin | -263.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cutia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 199 | -524 | 420 | 225 |
| 31 Mar 24 | 168 | -1,244 | 408 | 220 |
| 31 Dec 23 | 138 | -1,964 | 395 | 216 |
| 30 Sep 23 | 91 | -1,954 | 315 | 202 |
| 30 Jun 23 | 45 | -1,945 | 235 | 187 |
| 31 Mar 23 | 28 | -1,250 | 186 | 184 |
| 31 Dec 22 | 11 | -556 | 136 | 181 |
| 31 Dec 21 | 2 | -320 | 71 | 111 |
Quality Earnings: 2487 is currently unprofitable.
Growing Profit Margin: 2487 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2487's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2487's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2487 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).
Return on Equity
High ROE: 2487 has a negative Return on Equity (-44.12%), as it is currently unprofitable.